Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Kymera Therapeutics surged as much as 46% to a record high of $97.28 after announcing highly encouraging Phase 1b clinical data for its anti-inflammatory drug candidate, KT-621.</li><li>The once-daily oral pill demonstrated significant reductions in key Type 2 inflammation biomarkers, including STAT6 and fractional exhaled nitric oxide (FeNO), and was well-tolerated with a favorable safety profile.</li><li>These early findings have sparked investor enthusiasm, especially as KT-621 shows potential to rival injectable therapies like Regeneron’s Dupixent.</li></ul>

Kymera Therapeutics surged as much as 46% to a record high of $97.28 after announcing highly encouraging Phase 1b clinical data for its anti-inflammatory drug candidate, KT-621.The once-daily oral pill demonstrated significant reductions in key Type 2 inflammation biomarkers, including STAT6 and fractional exhaled nitric oxide (FeNO), and was well-tolerated with a favorable safety profile.These early findings have sparked investor enthusiasm, especially as KT-621 shows potential to rival injectable therapies like Regeneron’s Dupixent.

Kymera Therapeutics Surges 46%: A New Oral Challenger To Dupixent?

United States

Kymera Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Kymera Therapeutics serves customers in the State of Massachusetts.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kymera Therapeutics (KYMR US)

Kymera Therapeutics Surges 46%: A New Oral Challenger To Dupixent?

Kymera Therapeutics surged as much as 46% to a record high of $97.28 after announcing highly encouraging Phase 1b clinical data for its...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)